Cancer immunotherapy turns viral

OncoImmunology

Volumn 2, Issue 4, 2013, Pages

  Galluzzi, Lorenzo ^a,b,c   Lugli, Enrico ^d  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Amgen; Clinical trials; Immunotherapy; Melanoma; OncoVEXGM CSF; Talimogene laherparepvec

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONCOLYTIC HERPES VIRUS; TALIMOGENE LAHERPAREPVEC; TRASTUZUMAB; VEMURAFENIB;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CHILL; DOWN REGULATION; DRUG FEVER; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; HERPES SIMPLEX VIRUS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; LIFE EXPECTANCY; MELANOMA; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; SOLID TUMOR;

EID: 84886943960     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24802     Document Type: Article

References (18)

1. DeVita VT Jr., Rosenberg SA. Two hundred years of cancer research. N Engl J Med 2012; 366:2207-14; http://dx.doi.org/10.1056/ NEJMra1204479
2. Chen LL, Gouw L, Sabripour M, Hwu WJ, Benjamin RS. Combining targeted therapy with immunotherapy (interferon-α): Rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies. Oncoimmunology 2012; 1:773-6; http://dx.doi.org/10.4161/ onci.19729
3. Donia M, Fagone P, Nicoletti F, Andersen RS, Høgdall E, Straten PT, et al. BRAF inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology 2012; 1:1476-83; http://dx.doi. org/10.4161/onci.21940
4. Galluzzi L, Vacchelli E, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, et al. Trial Watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2012; 1:28-37; http://dx.doi.org/10.4161/ onci.1.1.17938
5. Mavilio D, Galluzzi L, Lugli E. Novel multifunctional antibody approved for the treatment of breast cancer. OncoImmunology 2013; 2:e24567; http://dx.doi. org/10.4161/onci.24567
6. Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, et al. Trial watch: Monoclonal antibodies in cancer therapy. Oncoimmunology 2013; 2:e22789; http://dx.doi. org/10.4161/onci.22789
7. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2:750-63; http://dx.doi.org/10.1038/nrc903
8. Dancey JE, Chen HX. Strategies for optimizing combinations of molecularly targeted anticancer agents. Nat Rev Drug Discov 2006; 5:649-59; http://dx.doi.org/10.1038/nrd2089
9. Galluzzi L, Senovilla L, Zitvogel L, Kroemer G. The secret ally: immunostimulation by anticancer drugs. Nat Rev Drug Discov 2012; 11:215-33; http://dx.doi.org/10.1038/nrd3626
10. Quetglas JI, John LB, Kershaw MH, Alvarez-Vallina L, Melero I, Darcy PK, et al. Virotherapy, gene transfer and immunostimulatory monoclonal antibodies. Oncoimmunology 2012; 1:1344-54; http://dx.doi.org/10.4161/ onci.21679
11. Cerullo V, Vähä-Koskela M, Hemminki A. Oncolytic adenoviruses: A potent form of tumor immunovirotherapy. Oncoimmunology 2012; 1:979-81; http://dx.doi.org/10.4161/ onci.20172
12. Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol 2012; 30:658-70; http://dx.doi.org/10.1038/nbt.2287
13. Kucharczuk JC, Randazzo B, Chang MY, Amin KM, Elshami AA, Sterman DH, et al. Use of a "replicationrestricted" herpes virus to treat experimental human malignant mesothelioma. Cancer Res 1997; 57:466-71.
14. Liu BL, Robinson M, Han ZQ, Branston RH, English C, Reay P, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 2003; 10:292-303; http://dx.doi.org/10.1038/ sj.gt.3301885
15. Vacchelli E, Galluzzi L, Eggermont A, Galon J, Tartour E, Zitvogel L, et al. Trial Watch: Immunostimulatory cytokines. Oncoimmunology 2012; 1:493-506; http://dx.doi.org/10.4161/ onci.20459
16. Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. A phase I study of OncoVEXGMCSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006; 12:6737-47; http://dx.doi.org/10.1158/1078-0432.CCR-06-0759
17. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factorencoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 2009; 27:5763-71; http:// dx.doi.org/10.1200/JCO.2009.24.3675
18. Kaufman HL, Bines SD. OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 2010; 6:941-9; http://dx.doi. org/10.2217/fon.10.66